Sanofi announced an investment of approximately $925 million (CAD) in a new vaccine manufacturing facility at its existing site in Toronto, Canada. The investment will provide additional antigen and filling capacity for Sanofi's FLUZONE high-dose quadrivalent influenza vaccine, increasing supply availability in Canada, the United States and Europe.
The federal government announced that it will invest $415 million in the project while the provincial government will add $55 million.
This new manufacturing facility will also grow Canada's bio-manufacturing sector and install industrial scale capacity to strengthen Canada's preparedness for future pandemics.
"This once-in-a-generation investment shows our government's commitment to rebuilding Canada's domestic biomanufacturing sector, focusing on both short-term strategic solutions and a long–term vision," said François-Philippe Champagne, Minister of Innovation, Science and Industry.
Following design, construction, testing and qualification of the facility and equipment, the new facility will be operational by 2026. Sanofi Pasteur's Toronto Site manufactures millions of doses of vaccines annually that help protect against pertussis, polio, diphtheria and tetanus for more than 60 countries worldwide.
Read the Sanofi statement